Aprea Therapeutics (NASDAQ:APRE – Get Free Report) and ZyVersa Therapeutics (NASDAQ:ZVSA – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.
Analyst Ratings
This is a breakdown of current recommendations and price targets for Aprea Therapeutics and ZyVersa Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aprea Therapeutics | 1 | 1 | 3 | 0 | 2.40 |
| ZyVersa Therapeutics | 0 | 0 | 0 | 0 | 0.00 |
Aprea Therapeutics presently has a consensus target price of $4.07, indicating a potential upside of 344.64%. Given Aprea Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Aprea Therapeutics is more favorable than ZyVersa Therapeutics.
Risk and Volatility
Profitability
This table compares Aprea Therapeutics and ZyVersa Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aprea Therapeutics | -4,405.59% | -61.03% | -50.24% |
| ZyVersa Therapeutics | N/A | -109.54% | -43.95% |
Earnings and Valuation
This table compares Aprea Therapeutics and ZyVersa Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aprea Therapeutics | $290,000.00 | 39.04 | -$12.60 million | ($1.54) | -0.59 |
| ZyVersa Therapeutics | N/A | N/A | -$9.41 million | ($0.83) | -0.23 |
ZyVersa Therapeutics has lower revenue, but higher earnings than Aprea Therapeutics. Aprea Therapeutics is trading at a lower price-to-earnings ratio than ZyVersa Therapeutics, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
34.2% of Aprea Therapeutics shares are held by institutional investors. Comparatively, 3.9% of ZyVersa Therapeutics shares are held by institutional investors. 13.6% of Aprea Therapeutics shares are held by company insiders. Comparatively, 0.2% of ZyVersa Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Aprea Therapeutics beats ZyVersa Therapeutics on 8 of the 13 factors compared between the two stocks.
About Aprea Therapeutics
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.
About ZyVersa Therapeutics
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. ZyVersa Therapeutics, Inc. was founded in 2014 and is headquartered in Weston, Florida.
Receive News & Ratings for Aprea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aprea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
